METHOD FOR PREDICTING THE PROBABILITY OF BIPHOSPHONATE OSTEONEKROSIS OF THE LOWER JAW IN THERAPY WITH ZOLENDRONIC ACID Russian patent published in 2022 - IPC G01T1/164 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and oncology, and can be used to predict the likelihood of bisphosphonate osteonecrosis of the lower jaw during therapy with zoledronic acid. The risk index of bisphosphonate osteonecrosis is calculated based on positron emission tomography scans (PET-CT scans). Wherein this index is calculated by the formula: RIBOPE = HU₂/HU₁=HU_FR1+HU_FRS1+HU_LEFT1, HU₂= HU_FR2+ HU_FRS2+ HU_LEFT2, where HU₁ is the sum of the values ​​of the initial optical density in the lateral and frontal areas of the lower jaw, HU_FR1 is the value of the initial optical density in the anterior part of the lower jaw, HUPR1 is the value of the initial optical density in the lateral right part of the lower jaw, HU_LEFT1 is the value of the initial optical density in the lateral left section of the lower jaw; HU₂ is the sum of the optical density values ​​in the lateral and frontal areas of the lower jaw during therapy with zoledronic acid, HU_FR2 is the optical density value in the frontal part of the lower jaw during therapy with zoledronic acid, HU_FRS2 is the optical density value in the lateral right part of the lower jaw during therapy with zoledronic acid. acid, HU_LEFT2 is the optical density value in the lateral left part of the lower jaw during therapy with zoledronic acid. If the RIBOPE value is < 1.07, the development of bisphosphonate osteonecrosis of the lower jaw is predicted, and if the RIBOPE value is ≥ 1.07, the development of the bisphosphonate osteonecrosis of the lower jaw is not predicted.

EFFECT: method provides a prognosis of the development of bisphosphonate osteonecrosis of the lower jaw during therapy with zoledronic acid due to quantitative data from PET-CT.

1 cl, 2 dwg, 3 ex